3 - Pear Therapeutics, Inc. (0001835567) (Issuer)

4 - Pear Therapeutics, Inc. (0001835567) (Issuer)

4 - Pear Therapeutics, Inc. (0001835567) (Issuer)

3 - Pear Therapeutics, Inc. (0001835567) (Issuer)

3 - Pear Therapeutics, Inc. (0001835567) (Issuer)

4 - Pear Therapeutics, Inc. (0001835567) (Issuer)

4 - Pear Therapeutics, Inc. (0001835567) (Issuer)

4 - Pear Therapeutics, Inc. (0001835567) (Issuer)

4 - Pear Therapeutics, Inc. (0001835567) (Issuer)

4 - Pear Therapeutics, Inc. (0001835567) (Issuer)

25-NSE - Thimble Point Acquisition Corp. (0001835567) (Subject)

425 - Thimble Point Acquisition Corp. (0001835567) (Subject)

8-K - Thimble Point Acquisition Corp. (0001835567) (Filer)

425 - Thimble Point Acquisition Corp. (0001835567) (Subject)

8-K - Thimble Point Acquisition Corp. (0001835567) (Filer)

425 - Thimble Point Acquisition Corp. (0001835567) (Subject)

8-K - Thimble Point Acquisition Corp. (0001835567) (Filer)

DEFA14A - Thimble Point Acquisition Corp. (0001835567) (Filer)

425 - Thimble Point Acquisition Corp. (0001835567) (Subject)

425 - Thimble Point Acquisition Corp. (0001835567) (Subject)

Publicly traded company called Pear Therapeutics, Inc. to begin trading on Nasdaq under ticker symbol "PEAR" starting December 6, 2021 Total expected gross proceeds from transaction totaling approximately $175 million Pear Therapeutics, Inc. ("Pear Therapeutics"), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), announced today the completion of its business combination with Thimble Point Acquisition Corp. ("Thimble Point") (NASDAQ:THMA), a special purpose acquisition company ("SPAC"). The publicly traded company will be known as Pear Therapeutics, Inc. and will commence trading on Nasdaq under the ticker symbol "

Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced management will participate in the Evercore ISI Fourth Annual HealthCONx Conference on Wednesday, December 1, 2021. Corey McCann, M.D., Ph.D., President and CEO, will participate in a virtual fireside chat at 8:50 a.m. ET. A live audio webcast can be accessed by clicking here and will be made available on Pear's website at www.peartherapeutics.com. A replay will be available for approximately 30 days following the live presentation. About Pear Therapeutics Pear Therapeutics is the leader in prescription digital therapeutics, or PD

Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its reSET-A™ PDT product candidate designed for the treatment of alcohol use disorder (AUD). reSET-A potentially expands Pear's addiction franchise, which includes FDA-authorized products to treat substance use disorder (SUD) and opioid use disorder (OUD). This is the second such Breakthrough Device Designation received by Pear, following the designation awarded for reSET-O®, the first ever for a PDT, which was for the treatment

Pear Therapeutics, Inc. ("Pear"), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), today provides an update on significant progress in its commercialization, pipeline, and platform strategy prior to the expected closing of its business combination with Thimble Point Acquisition Corp. (NASDAQ:THMA). Pear has demonstrated expanded payor reimbursement, increased prescribing, and extensive real-world product performance. In addition, Pear's pipeline and platform offer an opportunity to create and commercialize PDTs across many disease states. "The rapidly emerging PDT category is building momentum with accelerating clinical

Increases minimum gross proceeds from PIPE and Sponsor to $175 million Removes minimum cash as a condition to the closing of the business combination PIPE Investors have agreed to lock-up 82.4% of the PIPE shares Today, Thimble Point Acquisition Corp, Inc. (NASDAQ:THMA) ("Thimble Point"), a special purpose acquisition company, Pear Therapeutics, Inc. ("Pear"), the leader in developing and commercializing software to treat serious disease, called prescription digital therapeutics (PDTs), and an affiliate of Thimble Point's sponsor, jointly announced an additional commitment from an affiliate of Thimble Point's sponsor of up to $50 million. This press release features multimedia. View the

Pear's prescription digital therapeutics (PDTs), reSET® and reSET-O®, are included on the November 2021 MassHealth Drug List Summary Update and MassHealth Non-Drug Product List, effective November 1, 2021 MassHealth is now covering reSET and reSET-O for the treatment of substance use disorder and opioid use disorder, respectively, giving Massachusetts Medicaid patients access to innovative FDA-authorized addiction treatments via their mobile devices Massachusetts is the first state to cover PDTs for all Medicaid patients Pear's reSET and reSET-O will be paid for through MassHealth's Pharmacy Online Processing System (POPS) and do not require prior authorization Pear Therapeutics

Pear Therapeutics, Inc., the leader in developing and commercializing prescription digital therapeutics (PDTs) to treat serious disease, today announced management's participation in the virtual BTIG Digital Health Forum being held on Monday, November 15. Corey McCann, M.D., Ph.D., President and CEO, will participate in a panel discussion at 2:00 p.m. ET. The panel, "Setting the Pace: Commercializing Prescription Digital Therapeutics (PDTs) and Expanding the Pipeline," will be moderated by Marie Thibault, BTIG Medical Technology and Digital Health Analyst. BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG

Special meeting of Thimble Point Acquisition (NASDAQ:THMA) shareholders to approve the proposed business combination scheduled for November 23, 2021 at 9:00 a.m. Eastern Time Upon Closing, the Combined Company will trade on the NASDAQ under the ticker symbol "PEAR" Based on reported first half revenues and a preliminary review of third quarter revenue, Pear reaffirms its 2021 guidance of $4.0 million in revenue Pear Therapeutics, Inc. ("Pear"), the leader in developing and commercializing prescription digital therapeutics ("PDTs") to treat serious disease, and Thimble Point Acquisition Corp. ("Thimble Point") (NASDAQ:THMA) announced today that the U.S. Securities and Exchange Commi

Kirthiga Reddy, Partner at SoftBank Investment Advisers, and Alison Bauerlein, co-founder, Chief Financial Officer and Executive Vice President of Finance at Inogen, are nominees to become directors of Thimble Point Acquisition Corp. (NASDAQ:THMA), which will be renamed Pear Holdings Corp. upon the closing of the previously announced business combination of THMA and Pear Therapeutics, Inc. Both nominees are expected to bring deep commercialization experience in technology and healthcare to the combined company at a commercial inflection point Pear Therapeutics, Inc. ("Pear"), the leader in developing and commercializing prescription digital therapeutics ("PDTs") to treat serious disea

Pear Therapeutics, Inc. ("Pear") has built the first end-to-end platform for prescription digital therapeutics (PDTs), which are FDA-authorized, clinician-prescribed, and payor-reimbursed software that directly treats serious diseases Business combination with Thimble Point Acquisition Corp. (NASDAQ:THMA) (the "Business Combination") represents a pro forma equity value of approximately $1.6 billion and is expected to provide approximately $400 million in gross proceeds Business Combination includes up to $276 million of funds held in Thimble Point's trust account and a $125 million upsized private investment in public equity (the "PIPE") Fully committed PIPE investment anchored by

SC 13G - Pear Therapeutics, Inc. (0001835567) (Subject)

SC 13D - Pear Therapeutics, Inc. (0001835567) (Subject)

SC 13D - Pear Therapeutics, Inc. (0001835567) (Subject)

SC 13G - Pear Therapeutics, Inc. (0001835567) (Subject)

SC 13D - Pear Therapeutics, Inc. (0001835567) (Subject)

SC 13G - Pear Therapeutics, Inc. (0001835567) (Subject)

SC 13G - Pear Therapeutics, Inc. (0001835567) (Subject)

SC 13G - Thimble Point Acquisition Corp. (0001835567) (Subject)